HS-10375

Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-10375 is one of 29 small molecule programs targeting Lung Cancer. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

686 competitors in Lung Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

9 2

Libtayo

Regeneron

Preclinical

3 3

Vizimpro

Pfizer

Preclinical

3 4

Folvite

Xylocaine

2 6

Immunotherapy

Bristol-Myers Squibb

Preclinical

5 7

Paclitaxel and Carboplatin

Bristol-Myers Squibb

Preclinical

2 8

Rilotumumab

Amgen

Preclinical

2 9

Acupan

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Lung Cancer1 trial

Phase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1/2·NCT05435248·354 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HS-10375. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-10375 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-10375. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

HS-10375

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News